Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen

Doss-Gollin S, Thomas S, Brook B, et al. npj Vaccines. 2023;8(1):163. doi:10.1038/s41541-023-00759-y

VFI headquarters and Geneva laboratories

Rue du Champ-Blanchod 4
1228 Plan-les-Ouates
Switzerland

VFI Lausanne laboratories

Route de la Corniche 5
1066 Epalinges
Switzerland

contact@vformulation.org
VFI on LinkedIn

© 2025 Vaccine Formulation Institute